| Autor: |
Christopher J. Loftus, MD, Saneal Rajanahally, MD, Sarah K. Holt, PhD, Omer A. Raheem, MD, Kevin A. Ostrowski, MD, Thomas J. Walsh, MD, MS |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Sexual Medicine, Vol 8, Iss 4, Pp 673-678 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2050-1161 |
| DOI: |
10.1016/j.esxm.2020.08.003 |
| Popis: |
Introduction: Providers may use several treatment options for patients with Peyronie's disease; however, it is unclear whether practice patterns have evolved over recent years and if this has impacted cost. Aims: To investigate trends in the treatment of Peyronie's disease over time and the associated costs using a national, commercial insurance claims database. Methods: A retrospective cohort study was conducted using claims from the Truven MarketScan database from 2007 to 2018 for men with Peyronie's disease. Cost was estimated as either the sum of prescription oral or injectable treatment costs or as the single net cost associated with the operative procedure. Main Outcome Measures: Frequency of use of various treatments for Peyronie's disease and associated costs were assessed as trends over the timeline by year. Results: The estimated annual incidence of Peyronie's disease in this population rose from 61 to 77 per 100,000 patients over the included years, and the percent annual treatment rate rose from 17.8% to 26.2%. Colchicine was the most commonly prescribed oral agent in 2007 used in 22% of treated individuals; by 2018, pentoxifylline was the most common prescribed oral agent used in 33%. In 2007, 11% of treated patients received intralesional verapamil; however, by 2018, 24% received injectable collagenase, whereas |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
